🟢 Incyte is trading 10.59% up today on Q2 earnings beat and raised guidance

Incyte is trading at $131.46 (+10.59%) after second-quarter results beat estimates and management raised full-year guidance.

• The company reported $1.67 billion in revenue and $3.09 non-GAAP EPS, bolstered by a significant one-time CMS settlement benefit.
• Net sales for Opzelura surged 173% to $450 million, driving the stronger-than-expected quarterly performance.
• Investors are reacting positively to the raised full-year guidance and management's outlook for margin expansion.